

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
15 September 2022 (15.09.2022)



(10) International Publication Number
WO 2022/189679 A1

(51) International Patent Classification:

A61K 38/55 (2006.01) *A61K 38/57* (2006.01)
A61P 31/12 (2006.01) *A61P 25/02* (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- upon request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a)
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2022/061882

(22) International Filing Date:

03 May 2022 (03.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2021/061597
03 May 2021 (03.05.2021) EP
21206096.6 02 November 2021 (02.11.2021) EP
22168622.3 14 April 2022 (14.04.2022) EP

(71) Applicant: **ATLAS BIOTECHNOLOGY S.A.** [CH/CH];
Rue du Tir-au-Canon 4, 1227 Carouge (CH).

(72) Inventor: **ZHUKOVSKY, Nikolay**; Chemin du Ravin 11,
1292 Chambesey, Geneva (CH).

(74) Agent: **VOSSIUS & PARTNER PATENTANWÄLTE
RECHTSANWÄLTE MBB**; Siebertstraße 3, 81675
München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ALPHA-1-ANTITRYPSIN (AAT) IN THE TREATMENT AND/OR PREVENTION OF NEUROLOGICAL DISORDERS

(57) Abstract: The invention relates to a composition comprising a therapeutically effective amount of an alpha1-antitrypsin (AAT) protein, a variant, an isoform and/or a fragment thereof or a vector or a genetically modified cell comprising a sequence encoding AAT for use in the treatment and/or prevention of a disease or disorder of the nervous system or a symptom thereof.



WO 2022/189679 A1